CN101925365B - 具有低水溶解度的治疗性活性物质的纳米颗粒 - Google Patents

具有低水溶解度的治疗性活性物质的纳米颗粒 Download PDF

Info

Publication number
CN101925365B
CN101925365B CN200880125358XA CN200880125358A CN101925365B CN 101925365 B CN101925365 B CN 101925365B CN 200880125358X A CN200880125358X A CN 200880125358XA CN 200880125358 A CN200880125358 A CN 200880125358A CN 101925365 B CN101925365 B CN 101925365B
Authority
CN
China
Prior art keywords
active substance
derivant
nano
particle
nanoparticles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN200880125358XA
Other languages
English (en)
Chinese (zh)
Other versions
CN101925365A (zh
Inventor
P·库沃里尔
H·R·拉克尔雷蒂
F·多斯奥
B·斯特拉
L·卡特尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universite Paris Sud
Original Assignee
Universite Paris Sud
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universite Paris Sud filed Critical Universite Paris Sud
Publication of CN101925365A publication Critical patent/CN101925365A/zh
Application granted granted Critical
Publication of CN101925365B publication Critical patent/CN101925365B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nanotechnology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Epoxy Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
CN200880125358XA 2007-11-27 2008-11-27 具有低水溶解度的治疗性活性物质的纳米颗粒 Active CN101925365B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0708296 2007-11-27
FR0708296A FR2924024B1 (fr) 2007-11-27 2007-11-27 Nanoparticules d'actifs therapeutiques de faible solubilite aqueuse
PCT/FR2008/052147 WO2009071850A2 (fr) 2007-11-27 2008-11-27 Nanoparticules d'actifs therapeutiques de faible solubilite aqueuse

Publications (2)

Publication Number Publication Date
CN101925365A CN101925365A (zh) 2010-12-22
CN101925365B true CN101925365B (zh) 2013-03-06

Family

ID=39521786

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200880125358XA Active CN101925365B (zh) 2007-11-27 2008-11-27 具有低水溶解度的治疗性活性物质的纳米颗粒

Country Status (7)

Country Link
US (1) US8962552B2 (https=)
EP (1) EP2219678B1 (https=)
JP (1) JP5520228B2 (https=)
CN (1) CN101925365B (https=)
CA (1) CA2706933C (https=)
FR (1) FR2924024B1 (https=)
WO (1) WO2009071850A2 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2937537A1 (fr) 2008-10-29 2010-04-30 Centre Nat Rech Scient Nanoparticules de statine
US9517476B2 (en) * 2008-10-31 2016-12-13 Hitachi Koki Co., Ltd. Centrifuge with acceleration and deceleration time display
WO2010063080A1 (en) 2008-12-05 2010-06-10 Commonwealth Scientific And Industrial Research Organisation Amphiphile prodrugs
FR2988092B1 (fr) 2012-03-16 2014-04-25 Centre Nat Rech Scient Complexes de vitamine c, nanoparticules desdits complexes, procedes pour leur preparation, leurs compositions, leurs utilisations cosmetiques et procede de traitement cosmetique
EP2846773A4 (en) 2012-05-10 2015-12-30 Painreform Ltd DEPOT FORMULATIONS OF A LOCAL ANESTHETICS AND METHOD FOR THE MANUFACTURE THEREOF
CN103421085B (zh) * 2012-05-18 2015-07-29 中国科学院上海药物研究所 用于增加紫杉醇或以紫杉醇结构为基础的类似药物的溶解度的寡肽
CN103351424B (zh) * 2013-06-09 2016-05-04 东南大学 一种紫杉醇或多烯紫杉醇奥曲肽偶联物的制备方法
DK3204413T3 (da) * 2014-10-06 2019-12-09 Mayo Found Medical Education & Res Bærerantistofsammensætninger og fremgangsmåder til fremstilling og anvendelse heraf
TW201713360A (en) 2015-10-06 2017-04-16 Mayo Foundation Methods of treating cancer using compositions of antibodies and carrier proteins
SG11201802832UA (en) 2015-10-07 2018-05-30 Sumitomo Dainippon Pharma Co Ltd Pyrimidine compound
CA3107409A1 (en) 2018-07-23 2020-01-30 Japan As Represented By Director General Of National Institute Of Infectious Diseases Composition containing influenza vaccine
EP3598982A1 (en) * 2018-07-23 2020-01-29 Centre National De La Recherche Scientifique Bioconjugates of neuropeptides derivatives
FR3110427B1 (fr) 2020-05-20 2023-07-14 Laboratoires Eriger Conjugué terpenique de couplage
JP2025535561A (ja) * 2022-12-19 2025-10-24 元樟生物科技股▲フン▼有限公司 薬物リンカーおよびリンカー共役化合物
CN119613473B (zh) * 2024-12-06 2026-02-27 大连医科大学 阿霉素-角鲨烯小分子前药及其制备方法和应用
CN120210296A (zh) * 2025-03-27 2025-06-27 安徽天寅生物技术有限公司 一种纳米级水溶性角鲨烯的制备工艺

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5399554A (en) * 1989-02-02 1995-03-21 Ajinomoto Co., Inc. Readily soluble 2',3'-dideoxyinosine compositions
WO1999012545A2 (en) * 1997-09-05 1999-03-18 Glaxo Group Limited Medicaments containing acyclovir
WO2000071079A2 (en) * 1999-05-21 2000-11-30 American Bioscience, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5489589A (en) * 1994-12-07 1996-02-06 Bristol-Myers Squibb Company Amino acid derivatives of paclitaxel
US20050191359A1 (en) * 2001-09-28 2005-09-01 Solubest Ltd. Water soluble nanoparticles and method for their production
US20040092428A1 (en) * 2001-11-27 2004-05-13 Hongming Chen Oral pharmaceuticals formulation comprising paclitaxel, derivatives and methods of administration thereof
EP1498120A1 (en) 2003-07-18 2005-01-19 Aventis Pharma S.A. Semi-solid formulations for the oral administration of taxoids
US20050100577A1 (en) * 2003-11-10 2005-05-12 Parker Theodore L. Expandable medical device with beneficial agent matrix formed by a multi solvent system
FR2874016B1 (fr) * 2004-06-30 2006-11-24 Centre Nat Rech Scient Cnrse Nanoparticules de derives de la gemcitabine
US20060198940A1 (en) * 2005-03-04 2006-09-07 Mcmorrow David Method of producing particles utilizing a vibrating mesh nebulizer for coating a medical appliance, a system for producing particles, and a medical appliance

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5399554A (en) * 1989-02-02 1995-03-21 Ajinomoto Co., Inc. Readily soluble 2',3'-dideoxyinosine compositions
WO1999012545A2 (en) * 1997-09-05 1999-03-18 Glaxo Group Limited Medicaments containing acyclovir
WO2000071079A2 (en) * 1999-05-21 2000-11-30 American Bioscience, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Duan-Yun Si et. al..《Biomedical evaluation of nanomedicines》.《Asian Journal of Pharmacodynamics and Pharmacokinetics》.2007,第7卷(第2期),第83-97页. *
G. Pasut, F.M. Veronese.《Polymer–drug conjugation, recent achievements and general strategies》.《PROCESS IN POLYMER SCIENCE》.2007,第32卷(第8-9期),第933-961页. *
Kingston DG, Newman DJ..《Taxoids: cancer-fighting compounds from nature》.《Curr Opin Drug Discov Devel.》.2007,第10卷(第2期),第130-144页. *
Patrick Couvreur et. al..《Squalenoyl Nanomedicines as Potential Therapeutics》.《NANO LETTERS》.2006,第6卷(第11期),第2544-2548页. *

Also Published As

Publication number Publication date
FR2924024A1 (fr) 2009-05-29
WO2009071850A2 (fr) 2009-06-11
FR2924024B1 (fr) 2012-08-17
EP2219678A2 (fr) 2010-08-25
US8962552B2 (en) 2015-02-24
WO2009071850A3 (fr) 2009-11-26
WO2009071850A8 (fr) 2009-09-17
CA2706933A1 (fr) 2009-06-11
CN101925365A (zh) 2010-12-22
US20100305030A1 (en) 2010-12-02
JP5520228B2 (ja) 2014-06-11
EP2219678B1 (fr) 2021-05-19
JP2011506276A (ja) 2011-03-03
CA2706933C (fr) 2016-07-05

Similar Documents

Publication Publication Date Title
CN101925365B (zh) 具有低水溶解度的治疗性活性物质的纳米颗粒
US11413281B2 (en) Ternary conjugate of antitumor drug, and synthesis and application
US12343323B2 (en) Taxane-lipid-polysaccharide dual conjugates, preparation methods thereof and uses thereof
US6500461B2 (en) Particulate formulations
US8044034B2 (en) Nanoparticle derivatives of gemcitabine
EP2913064A1 (en) Branched drug-linker conjugates for the coupling to biological targeting molecules
JP2010526091A (ja) 癌の処置のための生物学的な標的基の改変
CZ2002928A3 (cs) Taxanová proléčiva
WO2018171164A1 (zh) 一种喜树碱类前药及其制备和应用
KR101064901B1 (ko) 난수용성 항암제와 신규 블록 공중합체를 포함하는 미셀조제물
CN111494640A (zh) 氧化还原双敏感三硫键桥连二聚体前药及其自组装纳米粒
CN107335060A (zh) 一类基于rgd多肽-化疗药物的小分子偶联物及其纳米前药系统
KR101743399B1 (ko) 폴리에틸렌글리콜과 트리페닐포스포늄이 컨쥬게이트된 물질 및 이를 적용한 미토콘드리아 표적 자기조립형 나노약물 전달체
CN106620717B (zh) 一种具有逆转肿瘤多药耐药性功能的两亲性缀合物抗肿瘤纳米药及其制备方法和应用
JP2004529116A (ja) タキサンプロドラッグ
CN105233298A (zh) 一种紫杉醇类磷脂化合物、其药物组合物及应用
CN105131039B (zh) 一种喜树碱类磷脂化合物、其药物组合物及应用
CN112089845A (zh) 紫杉烷类药物-阿霉素前药自组装纳米粒及其应用
CN1875022B (zh) 生育酚修饰的治疗性药物化合物
CN115252810A (zh) 一种可变形态的喜树碱多肽纳米制剂及其制备方法和应用
CN113398276B (zh) 脑胶质瘤靶向小檗碱与叶酸修饰的脂质材料的制备与应用
CN102114247A (zh) 生长抑素类似物-聚乙二醇-抗肿瘤药物偶联物及其制备
AU2023242296A1 (en) Peptidic water-soluble delivery system of anticancer drugs
CN119798356B (zh) 一种紫杉醇分子伞递送系统前药及其制备方法和应用
US11464864B2 (en) Drug-bound compound and use thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant